Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

Maren H. Harms; Gideon M. Hirschfield; Annarosa Floreani; Marlyn J. Mayo; Albert Parés; Alexander Liberman; Elizabeth Smoot Malecha; Richard Pencek; Leigh MacConell; Bettina E. Hansen

doi:10.1016/j.jhepr.2020.100191

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

Maren H. Harms, Gideon M. Hirschfield, Annarosa Floreani, Marlyn J. Mayo, Albert Parés, Alexander Liberman, Elizabeth Smoot Malecha, Richard Pencek, Leigh MacConell, Bettina E. Hansen

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background & Aims: Biochemical markers, including GLOBE score and aspartate aminotransferase-to-platelet ratio index (APRI), are used to stratify risk in patients with primary biliary cholangitis (PBC). This study aimed to evaluate the effects of obeticholic acid (OCA) on categorical shifts in GLOBE score, APRI, and both combined, based on data from POISE, a phase III placebo-controlled trial in patients with PBC who had an incomplete response or were intolerant to ursodeoxycholic acid. Methods: In a post hoc analysis, baseline and Month 12 data from POISE were used to calculate the APRI and GLOBE score. Patients were stratified into 3 risk groups based on a combination of APRI (0.54) and GLOBE (0.3 or age-specific) thresholds. Results: The analysis included 215 patients (47 low risk; 79 moderate risk; 89 high risk). Using the combined GLOBE score (threshold of 0.3) and APRI thresholds, there was improvement in ≥1 risk stage in 37% and 35% of patients in the OCA 5–10 mg and 10 mg groups, respectively, vs. 12% in the placebo group (both p <0.05). Progression occurred in 10% and 0% in the 5–10 mg and 10 mg groups vs. 37% in the placebo group. Results with GLOBE age-specific thresholds were similar. Conclusions: Based on change in APRI and GLOBE score at 12 months, OCA treatment is associated with reduction in the predicted risk of liver-related complications in patients with PBC. Lay summary: Primary biliary cholangitis (PBC) is a chronic disease affecting the liver. People who suffer from PBC are at risk of serious long-term complications. Information from certain blood tests can be used to estimate the likelihood of experiencing long-term complications. The results of this study showed that based on blood test results, people taking obeticholic acid, with or without ursodeoxycholic acid, for PBC were predicted to have a better outcome than those taking placebo. Clinical trials registration: NCT01473524.

Original language	English (US)
Article number	100191
Journal	JHEP Reports
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/j.jhepr.2020.100191
State	Published - Feb 2021

Keywords

APRI
Cholestasis
PBC
Risk stratification

ASJC Scopus subject areas

Gastroenterology
Internal Medicine
Immunology and Allergy
Hepatology

Access to Document

10.1016/j.jhepr.2020.100191

Cite this

Harms, M. H., Hirschfield, G. M., Floreani, A., Mayo, M. J., Parés, A., Liberman, A., Malecha, E. S., Pencek, R., MacConell, L., & Hansen, B. E. (2021). Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports, 3(1), Article 100191. https://doi.org/10.1016/j.jhepr.2020.100191

@article{635f39a571594f9b95b44d09a6cd73c5,

title = "Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis",

abstract = "Background & Aims: Biochemical markers, including GLOBE score and aspartate aminotransferase-to-platelet ratio index (APRI), are used to stratify risk in patients with primary biliary cholangitis (PBC). This study aimed to evaluate the effects of obeticholic acid (OCA) on categorical shifts in GLOBE score, APRI, and both combined, based on data from POISE, a phase III placebo-controlled trial in patients with PBC who had an incomplete response or were intolerant to ursodeoxycholic acid. Methods: In a post hoc analysis, baseline and Month 12 data from POISE were used to calculate the APRI and GLOBE score. Patients were stratified into 3 risk groups based on a combination of APRI (0.54) and GLOBE (0.3 or age-specific) thresholds. Results: The analysis included 215 patients (47 low risk; 79 moderate risk; 89 high risk). Using the combined GLOBE score (threshold of 0.3) and APRI thresholds, there was improvement in ≥1 risk stage in 37% and 35% of patients in the OCA 5–10 mg and 10 mg groups, respectively, vs. 12% in the placebo group (both p <0.05). Progression occurred in 10% and 0% in the 5–10 mg and 10 mg groups vs. 37% in the placebo group. Results with GLOBE age-specific thresholds were similar. Conclusions: Based on change in APRI and GLOBE score at 12 months, OCA treatment is associated with reduction in the predicted risk of liver-related complications in patients with PBC. Lay summary: Primary biliary cholangitis (PBC) is a chronic disease affecting the liver. People who suffer from PBC are at risk of serious long-term complications. Information from certain blood tests can be used to estimate the likelihood of experiencing long-term complications. The results of this study showed that based on blood test results, people taking obeticholic acid, with or without ursodeoxycholic acid, for PBC were predicted to have a better outcome than those taking placebo. Clinical trials registration: NCT01473524.",

keywords = "APRI, Cholestasis, PBC, Risk stratification",

author = "Harms, {Maren H.} and Hirschfield, {Gideon M.} and Annarosa Floreani and Mayo, {Marlyn J.} and Albert Par{\'e}s and Alexander Liberman and Malecha, {Elizabeth Smoot} and Richard Pencek and Leigh MacConell and Hansen, {Bettina E.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = feb,

doi = "10.1016/j.jhepr.2020.100191",

language = "English (US)",

volume = "3",

journal = "JHEP Reports",

issn = "2589-5559",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

AU - Harms, Maren H.

AU - Hirschfield, Gideon M.

AU - Floreani, Annarosa

AU - Mayo, Marlyn J.

AU - Parés, Albert

AU - Liberman, Alexander

AU - Malecha, Elizabeth Smoot

AU - Pencek, Richard

AU - MacConell, Leigh

AU - Hansen, Bettina E.

PY - 2021/2

Y1 - 2021/2

N2 - Background & Aims: Biochemical markers, including GLOBE score and aspartate aminotransferase-to-platelet ratio index (APRI), are used to stratify risk in patients with primary biliary cholangitis (PBC). This study aimed to evaluate the effects of obeticholic acid (OCA) on categorical shifts in GLOBE score, APRI, and both combined, based on data from POISE, a phase III placebo-controlled trial in patients with PBC who had an incomplete response or were intolerant to ursodeoxycholic acid. Methods: In a post hoc analysis, baseline and Month 12 data from POISE were used to calculate the APRI and GLOBE score. Patients were stratified into 3 risk groups based on a combination of APRI (0.54) and GLOBE (0.3 or age-specific) thresholds. Results: The analysis included 215 patients (47 low risk; 79 moderate risk; 89 high risk). Using the combined GLOBE score (threshold of 0.3) and APRI thresholds, there was improvement in ≥1 risk stage in 37% and 35% of patients in the OCA 5–10 mg and 10 mg groups, respectively, vs. 12% in the placebo group (both p <0.05). Progression occurred in 10% and 0% in the 5–10 mg and 10 mg groups vs. 37% in the placebo group. Results with GLOBE age-specific thresholds were similar. Conclusions: Based on change in APRI and GLOBE score at 12 months, OCA treatment is associated with reduction in the predicted risk of liver-related complications in patients with PBC. Lay summary: Primary biliary cholangitis (PBC) is a chronic disease affecting the liver. People who suffer from PBC are at risk of serious long-term complications. Information from certain blood tests can be used to estimate the likelihood of experiencing long-term complications. The results of this study showed that based on blood test results, people taking obeticholic acid, with or without ursodeoxycholic acid, for PBC were predicted to have a better outcome than those taking placebo. Clinical trials registration: NCT01473524.

AB - Background & Aims: Biochemical markers, including GLOBE score and aspartate aminotransferase-to-platelet ratio index (APRI), are used to stratify risk in patients with primary biliary cholangitis (PBC). This study aimed to evaluate the effects of obeticholic acid (OCA) on categorical shifts in GLOBE score, APRI, and both combined, based on data from POISE, a phase III placebo-controlled trial in patients with PBC who had an incomplete response or were intolerant to ursodeoxycholic acid. Methods: In a post hoc analysis, baseline and Month 12 data from POISE were used to calculate the APRI and GLOBE score. Patients were stratified into 3 risk groups based on a combination of APRI (0.54) and GLOBE (0.3 or age-specific) thresholds. Results: The analysis included 215 patients (47 low risk; 79 moderate risk; 89 high risk). Using the combined GLOBE score (threshold of 0.3) and APRI thresholds, there was improvement in ≥1 risk stage in 37% and 35% of patients in the OCA 5–10 mg and 10 mg groups, respectively, vs. 12% in the placebo group (both p <0.05). Progression occurred in 10% and 0% in the 5–10 mg and 10 mg groups vs. 37% in the placebo group. Results with GLOBE age-specific thresholds were similar. Conclusions: Based on change in APRI and GLOBE score at 12 months, OCA treatment is associated with reduction in the predicted risk of liver-related complications in patients with PBC. Lay summary: Primary biliary cholangitis (PBC) is a chronic disease affecting the liver. People who suffer from PBC are at risk of serious long-term complications. Information from certain blood tests can be used to estimate the likelihood of experiencing long-term complications. The results of this study showed that based on blood test results, people taking obeticholic acid, with or without ursodeoxycholic acid, for PBC were predicted to have a better outcome than those taking placebo. Clinical trials registration: NCT01473524.

KW - APRI

KW - Cholestasis

KW - PBC

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85102214295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102214295&partnerID=8YFLogxK

U2 - 10.1016/j.jhepr.2020.100191

DO - 10.1016/j.jhepr.2020.100191

M3 - Article

C2 - 33319187

AN - SCOPUS:85102214295

SN - 2589-5559

VL - 3

JO - JHEP Reports

JF - JHEP Reports

IS - 1

M1 - 100191

ER -

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this